Skip to main content

Table 3 Characteristics of the patients of the Radboudumc

From: The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis

  All patients
(n = 57)
No NIV indication (n = 35, 61.4%) NIV indication (n = 22, 38.6%) P-value
Demographic and disease variables
 Male (%) 50.9 54.3 45.5 0.516
 Diagnosis ALS/PMA (% ALS) 87.7 88.6 86.4 0.805
 Onset Spinal/Bulbar/Both (%) 45.6 / 36.8 / 17.5 40.0 / 37.1 / 22.9 54.5 / 36.4 / 9.1 0.352
 Age at referral (years) 64.6 ± 12.7 61.4 ± 13.1 69.8 ± 10.3 0.014
 Disease duration (years) 1.9 ± 1.6 2.0 ± 1.6 1.8 ± 1.8 0.572
 Deceased (n) 34 19 15 0.298
Variables at HVS
 Interval referral and first assessment (weeks) 5.6 ± 5.1 6.6 ± 5.9 4.1 ± 2.9 0.056
 pCO2 at first evaluation (mmHg) 40.6 ± 6.3 37.92 ± 3.19 44.95 ± 7.70 <0.0001
 Bicarbonate at first evaluation (mmol/L) 26.7 ± 3.7 25.08 ± 2.51 29.23 ± 3.88 <0.0001
 Follow up until NIV (months)* 12 ± 6 12 ± 6 0 ± 0 -
  1. The groups are based on the presence of an NIV indication during the first assessment at the HVS. Values are mean ± SD unless stated otherwise. P-values: comparison between patients with and without an NIV indication at the first visit at the HVS, using t-tests and Pearson Chi-square. ALS Amyotrophic Lateral Sclerosis, PMA Progressive Muscular Atrophy, HVS Home Ventilation Services, NIV Non-invasive ventilation. *Only patients who received an NIV indication